Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMBENYL vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Cough suppression,Symptomatic relief of cough associated with colds or allergies
Management of mild to moderate pain,Reduction of fever
Each 5 m L contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 m L (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 m L per day.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Codeine: 2.5-3.5 h (terminal) with CYP2D6 poor metabolizers up to 6 h. Guaifenesin: 1-2 h.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Codeine is metabolized via CYP2D6 to morphine (active), CYP3A4 to norcodeine, and to a lesser extent via glucuronidation; bromodiphenhydramine is metabolized via CYP450 enzymes, primarily CYP2D6.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Renal: 60% unchanged codeine, 20% codeine-6-glucuronide; biliary/fecal: 20% as metabolites. Guaifenesin: renal 95% as unchanged drug and metabolites.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Codeine: 7-25% (albumin). Guaifenesin: negligible.
10-25% bound to albumin at therapeutic concentrations.
Codeine: 3-6 L/kg (extensive tissue distribution). Guaifenesin: 1-2 L/kg.
0.8-1.0 L/kg; suggests distribution into total body water.
Codeine: oral 90% (first-pass metabolism). Guaifenesin: oral 100% (well absorbed).
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
GFR 30-50 m L/min: use with caution, reduce dose by 25-50% and monitor for CNS depression. GFR <30 m L/min: avoid use or use with extreme caution; codeine accumulation risk.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Child-Pugh A: no adjustment needed. Child-Pugh B: use with caution, consider 50% dose reduction. Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Not recommended for children under 6 years. Children 6-12 years: 5 m L (1 teaspoonful) orally every 4-6 hours; maximum 20 m L per day. Children >12 years: adult dosing.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Initiate at 5 m L every 6 hours due to increased sensitivity to anticholinergic and CNS depressant effects; monitor for confusion, sedation, and urinary retention.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Risk of respiratory depression, especially in children; risk of opioid addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; CYP2D6 ultra-rapid metabolizers may convert codeine to morphine at higher rates, leading to fatal respiratory depression.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Respiratory depression; use in children <12 years contraindicated; risk of opioid-induced hyperalgesia; central nervous system depression; sedation; constipation; urinary retention; hypotension; anticholinergic effects; potential for misuse, abuse, and addiction; serotonin syndrome if used with other serotonergic drugs; adrenal insufficiency; risk of severe hypotension in volume-depleted patients; interactions with CNS depressants.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Children <12 years; post-operative management in children <18 years after tonsillectomy/adenoidectomy; respiratory depression; acute or severe bronchial asthma; known hypersensitivity to codeine, bromodiphenhydramine, or any component; concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days; gastrointestinal obstruction; paralytic ileus.
Hypersensitivity to acetaminophen or any component of the formulation
Zolpidem absorption is delayed and reduced when taken with food, especially high-fat meals. To achieve rapid onset of sleep, take on an empty stomach. Avoid grapefruit juice as it may increase zolpidem levels.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
FDA Pregnancy Category C. First trimester: Limited data; potential for fetal malformations (cleft palate, cardiac defects) based on animal studies with high-dose antihistamines. Second and third trimesters: Risk of neonatal respiratory depression, irritability, and withdrawal if used near term. Avoid in third trimester due to risk of premature closure of ductus arteriosus (codeine component).
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Codeine is excreted in breast milk (M/P ratio ~2.5); risk of neonatal opioid toxicity (CNS depression). Diphenhydramine may inhibit lactation and cause drowsiness in infant. Contraindicated during breastfeeding due to possible severe adverse reactions in neonates.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No established safe dose during pregnancy; avoid use. If unavoidable, use lowest effective dose for shortest duration. Pharmacokinetic changes (increased clearance, volume of distribution) may require dose adjustment, but due to risks, alternative therapy is recommended.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Ambien (zolpidem) is a non-benzodiazepine sedative-hypnotic used primarily for short-term insomnia. Avoid co-administration with alcohol or other CNS depressants. Use the lowest effective dose, especially in elderly patients, due to increased risk of falls and cognitive impairment. Monitor for complex sleep behaviors (e.g., sleep-driving). Tablet should be taken immediately before bedtime, not with or after a meal to avoid delayed onset.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take zolpidem exactly as prescribed, only when you have at least 7-8 hours to devote to sleep.,Do not take zolpidem with alcohol or other sedatives as this can cause severe drowsiness and dangerous side effects.,Avoid driving or operating machinery the morning after taking zolpidem, as it may cause drowsiness, dizziness, or impaired coordination.,Report any unusual behaviors during sleep, such as walking, eating, or driving, to your doctor immediately.,Do not crush, chew, or split the extended-release tablets; swallow them whole.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMBENYL vs INJECTAPAP, answered by our medical review team.
AMBENYL is a Antitussive/Antihistamine Combination that works by AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMBENYL and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMBENYL is: Each 5 m L contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 m L (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 m L per day.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMBENYL and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMBENYL is classified as Category C. FDA Pregnancy Category C. First trimester: Limited data; potential for fetal malformations (cleft palate, cardiac defects) based on animal studies with high-dose antihistamines. Se. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.